Article
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.
Cancer cell - 12 Jan 2026
Diamond Eli L, Emile Jean-Francois, Fujino Takeshi, Haroche Julien, Maron Maxim I, Lewis Alexander M, Rahman Jahan, Reiner Anne S, Bossert Dana, Rosenblum Marc, Yabe Mariko, Petrova-Drus Kseniya, Francis Jasmine H, Rotemberg Veronica, Rampal Raajit K, Yoo Sarah, Daniyan Anthony F, Mahajan Sonia, Hatzoglou Vaios, Young Robert, Ulaner Gary A, Rösler Wiebke, Hershkovitz-Rokah Oshrat, Shpilberg Ofer, Mazor Roei D, Chen Luke Y C, Singer Michael, Cuibus M Adriana, Weis Kenyon, Benbarche Salima, Zhang Pu, Fox Nina, Castro Cynthia, Tittley Steven, Witkowski Matthew, Cohen-Aubart Fleur, Terriou Louis, Hanoun Maher, Schleinitz Nicolas, Sosa Gabriela, Hautala Timo, De Lassus Laure Farnault, Rosen Neal, Abdel-Wahab Omar, Durham Benjamin H
Abstract excerpt
Histiocytic neoplasms are clonal disorders of the monocyte/macrophage lineage defined by mutations activating mitogen-activated protein kinase (MAPK) signaling. Recently, the MEK1/2 inhibitor cobimetinib was FDA-approved for patients with adult histiocytoses. Here, aided by a prospective registry of patients with histiocytoses (NCT03329274), we identify that MEK1/2 mutations which constitutively activate MEK...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.